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Background: Glasgow Prognostic Score (GPS) has been reported as a powerful prognostic tool for patients with
advanced non–small cell lung cancer (NSCLC). The aim of this study was to assess the relationship between GPS
and prognosis related tumor markers in patients with advanced NSCLC.
Methods: We included 138 advanced NSCLC patients and twenty healthy controls in the study. GPS was calculated
by combined serum C-reactive protein (CRP) and albumin. Three serum tumor markers, which included cytokeratin
19 fragment antigen 21-1 (CYFRA21–1), carcinoembryonic antigen (CEA) and tissue polypeptide specific antigen
(TPS), were detected by enzyme-linked immunosorbent assay (ELISA). GPS and tumor markers were all assessed
before chemotherapy. All patients received at least 2 courses of cisplatin-based chemotherapy. After that, 2 to
5 years follow-up was conducted.
Results: Median levels of CYFRA21–1 were 1.5 ng/ml (0.1–3.1 ng/ml) in healthy controls, and 4.6 ng/ml
(0.7–35.2 ng/ml) in GPS 0 advanced NSCLC, 11.2 ng/ml (0.4–89.2) ng/ml in GPS 1 advanced NSCLC, and 15.7 ng/ml
(2.9–134.6 ng/ml) in GPS 2 advanced NSCLC, respectively. Median levels of CYFRA21-1 were higher in NSCLC
patients than in healthy controls, and CYFRA21-1 increased gradually according to GPS category in NSCLC patients
(P < 0.05). Similar results were found for median levels of CEA and TPS in healthy controls and NSCLC patients
(P < 0.05). In NSCLC patients, positive correlations were found between CYFRA21-1 and GPS, CEA and GPS, TPS and
GPS. The Spearman’s rank correlation coefficient were 0.67 (P < 0.05), 0.61 (P < 0.05) and 0.55 (P < 0.05), respectively.
Survival analyses showed GPS was an independent prognostic factor for advanced NSCLC. CYFRA21-1(>3.3 ng/ml)
and TPS (>80 U/l) were related with the prognosis of advanced NSCLC by univariate analyses, but multivariate
analyses showed CYFRA21-1, TPS and CEA were not the independent prognostic factors for advanced NSCLC.
Conclusions: Our results showed GPS were positive correlated with CYFRA21-1, CEA and TPS in patients with
advanced NSCLC. However, GPS was more efficient in predicting prognosis of advanced NSCLC than these three
single prognosis related tumor markers.
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Although many progresses have been made in targeted
therapy, chemotherapy and radiotherapy in recent years,
the prognosis of advanced Non-small cell lung cancer
(NSCLC) is still poor, with the median overall survival
30.5 months and the median progression-free survival* Correspondence: pphss@126.com
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unless otherwise stated.10.8 months [1]. Accurate prediction of prognosis out-
come in advanced NSCLC also remains challenging.
Even within the same stage, same performance status,
same treatment group and same response to treatment,
survival varies from patient to patient [2].
Inflammatory responses play decisive roles at different
stages of tumor development, including initiation, pro-
motion, malignant conversion, invasion and metastasis
[3]. Glasgow prognostic score (GPS), a inflammation-
based scoring system, was found an useful tool inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jiang et al. BMC Cancer  (2015) 15:386 Page 2 of 6predicting prognosis for gastric cancer [4], colorectal
cancer [5], pancreatic cancer [6], hepatocellular can-
cer [7], esophageal cancer [8], and cervical cancer
[9]. In NSCLC patients, our previous study has also
found GPS was a useful and important predictor of
progression free survival (PFS) and overall survival
(OS) [10]. This conclusion also confirmed by other
studies [11–13].
In addition, several tumor markers have been de-
scribed to be independently relevant for estimation of
prognosis in terms of overall or progression-free survival
in NSCLC patients [14]. Cytokeratin 19 fragment anti-
gen 21–1 (CYFRA21-1) is a cytokeratin expressed in
simple epithelium, which has been extensively studied in
patients with NSCLC has been demonstrated to be
clinically useful. Serum concentrations of CYFRA 21–1
correlate with tumor burden, and CYFRA 21–1 is an inde-
pendent prognostic factor for NSCLC [15–17]. Carcinoem-
bryonic antigen (CEA) is an oncofetal glycoprotein of the
cell surfaces. The NSCLC patients with a persistently
high serum CEA level after had worst prognosis [18,
19]. One study showed patients with normal preopera-
tive serum CEA levels had better 5 year survival than
patients with high preoperative serum CEA levels (71.1 %
versus 54.6 %, P = 0.016) [20]. Tissue polypeptide specific
antigen (TPS) is another important prognosis related
tumor markers which has been confirmed by many stud-
ies [21, 22].
GPS and some tumor markers also have prognosis
predicting value in patients with NSCLC. However, the
relationship between GPS and tumor markers level is
still unknown. The aim of the present study was to exam-
ine the relationship between an inflammation-based GPS
and prognosis related tumor markers (CYFRA21-1, CEA
and TPS) level in patients with NSCLC.
Methods
Patients
Between January 2008 and January 2011, consecutive pa-
tients with stage IIIB or IV NSCLC were enrolled in this
prospective cohort study. All NSCLC diagnosis was con-
firmed by cytological or histological examination. Clin-
ical staging was based on clinical findings, chest X-ray,
computed tomography of the chest, abdomen, brain and
bone scintigraphy. Basic demographics, which included
age, gender, histological type, smoking status and Eastern
Cooperative Oncology Group Performance Status (ECOG’s
PS) were recorded before chemotherapy. We also en-
rolled 20 healthy volunteers as control group. The vol-
unteers have compared age, sex and smoking status
with NSCLC patients. The study was approved by the
Ethics Committee of Taizhou hospital, and all patients
and healthy control signed an informed consent before
inclusion in the study.GPS system
GPS were defined by combined serum C-reactive protein
(CRP) and albumin [4–13]. Patients with a CRP <10 mg/L
and albumin >35 g/L were allocated to GPS 0. If only CRP
was increased or albumin decreased patients were allocated
to the GPS 1, and patients in whom CRP was >10 mg/L
and albumin level <35 g/L were classified as GPS 2.
Before chemotherapy, 10 ml blood sample was collect.
5 ml sample was sent to the laboratory immediately.
CPR and albumin concentration were examined by
routine laboratory measurements. After that, GPS was
calculated.
Serum tumor markers
The remaining 5 ml serum sample was stored at −20 °C
for future analysis. CYFRA21-1, CEA and TPS measured
by enzyme-linked immunosorbent assay (ELISA) using
commercially available assay kits (Immuno-Biological
Laboratories, Gunma, Japan). All operations were followed
by manufacturer’s instructions. As recommended by the
manufacturers, the following cut-offs for serum levels
were used initially: CYFRA21-1 3.3 ng/ml, CEA 5 ng/ml,
and TPS 80 U/l.
Treatment and follow-up
Patients with ECOG’s PS 0–1 received at least 2 courses
of cisplatin-based chemotherapy and received courses
until the appearance of progressive disease. The cisplatin-
based regimens were vinorelbine (25 mg/m2) on days 1
and 8 plus cisplatin (80 mg/m2) on day 1 of a 21-day cycle,
and gemcitabine (1000 mg/m2) on days 1 and 8 plus cis-
platin (80 mg/m2) on day 1 of a 21-day cycle. Patients with
ECOG’s PS 2 received docetaxel (75 mg/m2) on days 1
and docetaxel (35 mg/m2) on days 1, days 8 and days 21
every 3 weeks. Patients with ECOG’s PS 3 only received
best support care.
All patients received 3 to 5 years follow-up. The out-
comes included progression free survival (PFS) and over-
all survival (OS).
Statistical analysis
Data are presented as medians, with ranges. The chi-square
test was used for categorical data (compare characteristics
between NSCLC patients and healthy controls). The
Kruscal-Wallis H test was used for non-normal distribution
continuous data for more than two populations (compare
tumor markers between GPS 0, GPS 1, GPS 2 NSCLC pa-
tients and healthy controls). Associations between GPS and
the level of serum tumor markers were analyzed using
Spearman’s rank correlation coefficient. Survival analyses
were conducted by univariate Kaplan–Meier method and
multivariate Cox proportional hazards model. Results were
presented as hazard ratio (HR) with 95% confidence
interval (95% CI). P < 0.05 was considered significant. All
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tics software (version 19.0, IBM, Armonk, NY).
Results
Characterization of NSCLC patients and healthy controls
One hundred thirty-eight NSCLC patients were included
in the study. Patients’ median age was 55 years (range,
37–81years), 63 (45.7 %) patients >60 years, 117 (84.8 %)
patients were male, and 42 (30.4 %) patients were smokers.
20 healthy controls and 138 NSCLC patients were similar
in terms of age, gender and smoking status. In 138 NSCLC
patients, 67 (48.6 %) patients had squamous cell carcin-
oma and 56 (59.6 %) had stage IV disease. and 82 (59.5 %)
patients had an ECOG performance status 0 or 1. Charac-
teristics of healthy controls and NSCLC patients were
listed in Table 1.
Relationship between GPS and serum tumor markers
Median levels of CYFRA21-1 were 1.5 ng/ml (0.1–
3.1 ng/ml) in healthy controls. In NSCLC patients, me-
dian levels of CYFRA21-1 were 4.6 ng/ml (0.7–35.2 ng/
ml) in GPS 0, 11.2 ng/ml (0.4–89.2) ng/ml in GPS 1, and
15.7 ng/ml (2.9–134.6 ng/ml) in GPS 2, respectively. The
Kruscal-Wallis H test showed median levels of CYFRA21-
1 were significant different between four groups (P < 0.05).
Median levels of CYFRA21-1 were higher in NSCLC pa-
tients than in healthy controls. In NSCLC patients, me-
dian levels of CYFRA21-1 increased gradually according
to GPS category. Similar results were found for median
levels of CEA and TPS in healthy controls and NSCLC
patients (P < 0.05). Figure 1 showed the trends of 3 serum
tumor markers in healthy controls and NSCLC patients.
In NSCLC patients, positive correlation was found be-
tween CYFRA21-1 and GPS. The Spearman’s rank correl-
ation coefficient was 0.67 (P < 0.05). Positive correlations
were also found between CEA and GPS, TPS and GPS.
The correlation coefficient were 0.61 (P < 0.05) and 0.55
(P < 0.05), respectively.
The relationship between advanced NSCLC prognosis and
GPS and serum tumor markers
Univariate analyses showed GPS was related with the
prognosis of advanced NSCLC. After adjusted by patients’Table 1 Characteristics of healthy controls and NSCLC patients
Characteristics Healthy controls (n = 20)
Age (≤60/>60) 12/8
Gender (M/F) 16/4
Smoking status (Y/N) 6/14
Histologic type (Squ/Ade/Oth) N/A
Stage (IIIB/IV) N/A
Performance status (0/1/2/3) N/A
Squ, Squamous cell carcinoma; Ade, Adenocarcinoma; Oth, Others; N/A, Not applicaage, gender, smoking status, histologic type, tumor stage,
performance status and serum tumor markers, the multi-
variate analyses confirmed that GPS was an independent
prognostic factor for advanced NSCLC.
For serum tumor markers, CYFRA21-1(>3.3 ng/ml)
and TPS (>80 U/l) were related with the prognosis of
advanced NSCLC by univariate analyses, but multivari-
ate analyses showed CYFRA21-1 and TPS were not the
independent prognostic factors for advanced NSCLC.
In univariate analyses and multivariate analyses, CEA
(>5 ng/ml) also didn’t show the relationship with the
prognosis of advanced NSCLC.
Details of univariate and multivariate survival analyses
were listed in the Table 2, and survival curves stratified
by GPS and serum tumor markers were shown in Fig. 2.
Discussion
Lung cancer is the most common cancer in world. Each
year, nearly 1,708,800 patients were diagnosed with lung
cancer and over 1,378,400 die, corresponding to an an-
nual age-standardized rate of 47.4 cases per 100,000 pa-
tients, annual age-standardized mortality rate of 39.4
deaths per 100,000 in more developed areas [23]. GPS
was found a useful prognosis predictor in patients with
NSCLC. Serum tumor markers, such as CYFRA21-1,
CEA and TPS have been also confirmed as important
prognosis risk factors for NSCLC [14–22]. The aim of
the present study was to examine the relationship be-
tween GPS and prognosis related tumor markers
(CYFRA21-1, CEA and TPS) level in patients with
NSCLC. We found the median levels of CYFRA21-1,
CEA and TPS were all higher in patients with NSCLC
compared with healthy controls. In patients with NSCLC,
CYFRA21-1, CEA and TPS were all increased gradually ac-
cording to GPS. The Spearman’s rank correlation showed
positive correlations existing between these three tumor
markers and GPS in NSCLC patients. Brown DJ and his
colleagues also compared GPS and serum biochemical var-
iables in patients with advanced lung and gastrointestinal
cancer, they also found found GPS were correlated with
the biochemical variables, which included sodium, chlor-
ide, creatine kinase, zinc, vitamin D, calcium, copper, alka-








Fig. 1 The distribution of three tumor markers in healthy control (n = 20) and NSCLC patients (GPS 0 n = 95; GPS 1 n = 32; GPS 2 n = 11). A:
cytokeratin 19 fragment (CYFRA21-1) concentration was significant deferent between four groups (P<0.05); B: carcinoembryonic antigen (CEA)
concentration was significant deferent between four groups (P<0.05); C: tissue polypeptide specific antigen (TPS) concentration was significant
deferent between four groups (P<0.05)
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study.
Some possible mechanisms maybe explain these corre-
lations between GPS and tumor markers. GPS is a can-
cer prognosis predicting system based on inflammation
scoring. Studies have confirmed that inflammatory acti-
vate immune cells product cytokines, such as NF- κB,
STAT3, AP-1, FOXP3 and interleukin, which can stimu-
late cancer cell proliferation and survival. That is a
major tumor-promoting mechanism for inflammatory
[3]. A recent study showed the relative expression of
transcription factor FOXP3 tended to increase expres-
sion of cytokeratin 19 [25]. Kim et al. also found tran-
scription factor NF-κB were related with elevated
carcinoembryonic antigen level [26]. For tumor marker
TPS, Kramer et al. found TPS increased along with
interleukin-8 (IL-8) [27]. Inflammation promote angio-
genesis is another important mechanism for tumor pro-
mote and metastasis. Important proangiogenic genes,
such as VEGF, CXCL1, CXCL8, IL-8 and HIF1a, are dir-
ectly regulated by inflammatory cytokines [3]. Yang et al.
reported the level of cytokeratin 19 was related to tumorTable 2 Relationship between advanced NSCLC prognosis and GPS
Characteristics Disease-Free survival
Univariate Multivariate
HR(95% CI) P HR(95% CI)
GPS
0 1 0.01* 1
1 0.7(0.4–0.9) 0.8(0.5–0.9)
2 0.5(0.2–0.8) 0.6(0.2–0.8)
CYFRA21-1 (>3.3 ng/ml) 0.6(0.5–0.9) 0.03* 0.7(0.5–1.0)
CEA (>5 ng/ml) 0.7(0.4–1.1) 0.13 0.7(0.5–1.2)
TPS (>80 U/l) 0.7(0.5–0.9) 0.04* 0.7(0.5–1.1)
*P < 0.05.angiogenesis [28]. VEGF is regarded as the strongest
angiogenic factor, which has been found related with
carcinoembryonic antigen [29].
Although we found GPS are positive correlated with
these tumor markers (CYFRA21-1, CEA and TPS) and
in advanced NSCLC patients. Survival analyses showed
GPS was an independent prognostic factor for advanced
NSCLC. While CYFRA21-1(>3.3 ng/ml), CEA (>5 ng/ml),
and TPS (>80 U/l) were not the independent prognostic
factors for advanced NSCLC. It seems GPS was more effi-
cient in predicting prognosis of advanced NSCLC than
these three single prognosis related tumor markers. No
other studies were found for assessing prognosis of lung
cancer by combine GPS and tumor markers. While in
colorectal cancer patients, Choi KW et al. found CEA and
GPS were associated with cancer-specific survival in uni-
variate analysis, but only GPS was identified as independ-
ent prognostic factors in multivariate analysis [30]. In
gastric cancer patients, Jiang X et al. reported increased
GPS, elevated CEA and CA19-9 predicted a higher
risk of postoperative mortality in both relative early-stage
(stage I; P < 0.001) and advanced-stage cancer (stage II, IIIand serum tumor markers in 138 patients
Overall survival
Univariate Multivariate
P HR(95% CI) P HR(95% CI) P
0.03* 1 0.02* 1 0.02*
0.8(0.5–0.9) 0.8(0.4–0.9)
0.5(0.3–0.8) 0.5(0.2–0.9)
0.08 0.7(0.3–0.9) 0.04* 0.8(0.5–1.0) 0.07
0.17 0.8(0.5–1.1) 0.19 0.8(0.6–1.3) 0.19
0.12 0.8(0.5–1.0) 0.05 0.8(0.4–1.1) 0.13
Fig. 2 Survival curves Stratified by GPS and serum tumor markers. A: for the progression-free survival. B: for the overall survival
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in multivariate analysis, only GPS predicted postoperative
mortality (OR 1.845; 95% CI 1.184–2.875; P = 0.007), not
CEA (OR 1.234; 95% CI 0.955–1.595; P = 0.107) and
CA19-9 (OR 1.213; 95% CI 0.916–1.605; P = 0.177) [31].
These results were same like our study.
There was a limitation in our study. We only investi-
gated the relationship between GPS and tumor markers
before chemotherapy. Chemotherapy treatment may
change GPS and serum tumor markers level, and the
change of GPS and serum tumor markers level may be
related with chemotherapy response. We don’t know
whether this relationship will continue to exist. However,
some blood samples were lost in the follow-up.Conclusions
The results of the present study show that GPS were
positive correlated with CYFRA21-1, CEA and TPS in
patients with advanced NSCLC. However, GPS was more
efficient in predicting prognosis of advanced NSCLC
than these three single prognosis related tumor markers.
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